🇺🇸 FDA
Patent

US 11685744

CDK inhibitors and their use as pharmaceuticals

granted A61KA61K31/4188A61K31/4196

Quick answer

US patent 11685744 (CDK inhibitors and their use as pharmaceuticals) held by Prelude Therapeutics, Incorporated expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Prelude Therapeutics, Incorporated
Grant date
Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
54
CPC classes
A61K, A61K31/4188, A61K31/4196, A61K31/506, A61K31/5355